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described in numerous cardiovascular disorders, such as
myocardial infarction,1 systemic hypertension,2 coro-
nary artery spasm,3 heart failure,4 and pulmonary
hypertension.5 The human lung is an important site of
metabolism for various circulating vasoactive amines
and peptides, including ET-1. Reduced clearance or
increased production by the pulmonary circulation
could contribute to increased circulating ET-1 levels in
different cardiovascular diseases.6
The plasma concentration of ET-1 increases progres-
sively during cardiopulmonary bypass (CPB).7 It is sug-
gested that ET-1 could act as a mediator of periopera-
tive vasospasm.8 In an experimental model, postbypass
E ndothelin 1 (ET-1) is an endothelium-derived pep-tide with strong vasoconstrictive and proliferative
actions. Increased circulating ET-1 levels have been
Background: Coronary artery bypass operations are associated with
increased circulating levels of the powerful vasoconstrictor endothelin 1. The
pulmonary circulation is an important site for both production and clearance
of endothelin 1. Lung endothelial injury resulting from cardiopulmonary
bypass could modify pulmonary endothelin 1 metabolism through an
increase in production, a reduction in removal, or a combination of both.
Methods: Pulmonary endothelin 1 kinetics were quantified by using the indi-
cator-dilution technique in patients undergoing coronary artery bypass graft-
ing with (n = 11) or without cardiopulmonary bypass (ie, beating heart; 
n = 10). Mixed venous endothelin 1 levels were also measured in samples
from the pulmonary artery, and systemic levels were obtained from the radi-
al artery.
Results: Pulmonary artery endothelin 1 levels were similar before and after
cardiopulmonary bypass, with means of 1.59 ± 0.37 pg/mL and 1.33 ± 0.15
pg/mL (P = .45), respectively. Systemic endothelin 1 levels, however,
increased after bypass from 1.64 ± 0.22 pg/mL to 2.07 ± 0.16 pg/mL 
(P = .01). In the beating heart group, endothelin 1 levels before and after the
operation were similar in the pulmonary artery (1.25 ± 0.27 pg/mL and 1.45
± 0.31 pg/mL, respectively; P = .38), as well as in the radial artery (1.70 ±
0.26 pg/mL and 1.73 ± 0.35 pg/mL, respectively; P = .92). The capacity to
clear endothelin 1 from the pulmonary circulation, as computed from the
permeability–surface area product for endothelin 1, was not affected by car-
diopulmonary bypass before and after the operation (25.19 ± 2.67 mL/s and
23.12 ± 4.39 mL/s, respectively; P = .49). It was similar and also unaffected
in the beating heart group.
Conclusion: Coronary artery bypass grafting with cardiopulmonary bypass is
associated with an increase in systemic endothelin 1 levels. The mechanism
involved is not related to a decreased pulmonary clearance of endothelin 1
from the systemic circulation but rather to an increased endothelin 1 release
by the lungs. (J Thorac Cardiovasc Surg 2001;121:1137-42)
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pulmonary hypertension was related to ET-1 produc-
tion during CPB.9 The mechanisms responsible for the
increase in systemic ET-1 levels during CPB, however,
remain largely unresolved. Ischemia-reperfusion with
subsequent endothelial injury could affect pulmonary
ET-1 metabolism during CPB. A decreased clearance
through the endothelial ETB receptor or an increased
production and release of ET-1 by the pulmonary cir-
culation could be involved. To test this hypothesis, we
quantified pulmonary tracer ET-1 kinetics by using a
dual-label indicator-dilution technique. To account for
possible net clearance or production, we obtained
simultaneous measurements of immunoreactive ET-1
levels across the pulmonary circulation. Studies were
performed in patients undergoing elective coronary
artery bypass grafting (CABG) with or without CPB.
Methods
The study protocol and consent form were approved by the
research and ethics committee of the Montreal Heart Institute.
Twenty-one subjects were recruited among patients undergo-
ing elective CABG procedures. Exclusion criteria were as
follows: history of heart failure with ejection fraction of less
than 40%; pulmonary hypertension (systolic value > 40 mm
Hg); chronic obstructive pulmonary disease; past pulmonary
operation; and renal failure with a creatinine level of greater
than 200 mmol/L.
The CABG procedures were done with CPB or with the
beating heart technique, depending on preference of the sur-
geon. In 11 patients CPB was performed by using moderate
hemodilution, with hematocrit levels maintained between
20% and 25% and systemic hypothermia between 32°C and
34°C. Antegrade blood cardioplegia was used for every
patient undergoing CABG with CPB. In 10 patients the
CABG operations were done by using the beating heart tech-
nique with a myocardial wall stabilizer.
The study protocol was carried out before and immediate-
ly after the operation in all the recruited patients. A pul-
monary artery catheter (Swan-Ganz catheter; Baxter
Healthcare Corp, Edwards Division, Santa Ana, Calif) and a
radial artery catheter were inserted before the operation.
Radial and pulmonary artery blood samples were simultane-
ously obtained in ethylenediamine tetraacetic acid tubes for
determination of plasma immunoreactive ET-1 levels by
using a competitive binding immunoassay, as previously
described in detail.10 A 5-cm extension with a 3-way stopcock
was added to the pulmonary artery catheter, and a 2-mL bolus
mixture for the indicator-dilution study was introduced into
the catheter (the bolus was completely contained within the
injection system). The radial artery catheter was connected to
a Masterflex roller pump (Cole-Parmer Instrument Company,
Vernon Hills, Ill) that was connected in turn to a circular frac-
tion collector. The experiment was carried out by rapidly
flushing the bolus with 10 mL of the patient’s blood while
simultaneously collecting radial artery blood in 60 consecu-
tive tubes (1.2 seconds per tube) at a rate of 50 mL/min. A 2-
mL sample of blood was then taken from the injection lines
to determine the amount of residual activity retained in the
injection system.
The injection mixture was prepared under sterile condi-
tions. Human albumin (25%) was added to 3 mL of Evans
blue dye (5 mg/mL) to obtain a final bolus concentration of
4% albumin. The blue dye tightly binds to albumin and serves
as a vascular reference from which tracer ET-1 kinetics are
computed. Iodine 125–labeled ET-1 (10 µCi) (Dupont,
Wilmington, Del; NEN Life Science Products, Inc, Boston,
Mass; 2200 Ci/mmol) was then added to the mixture. The
final volume was approximately 3.5 mL per experiment; 2
mL was taken to constitute the bolus administered to the
patient, and the remaining 1.5 mL was kept for the prepara-
tion of dilution curve standards. All collected tubes, 1:10 and
1:100 diluted standards, and injection line samples were
treated identically. Blood (200 µL) was pipetted from each
tube and assayed in a gamma counter to determine iodine 125
activity. The remaining samples were centrifuged at 3000
rpm for 10 minutes, and 100 µL of plasma was drawn and
added to 1.0 mL of 0.9% NaCl in spectrophotometer cuvettes
for measurement of Evans blue dye absorbance (620 nm
minus 740 nm). The exact quantity of tracers injected was
determined by subtracting the activity retained in the injec-
tion system from the amount contained in the 2-mL bolus.
For each sample, the fractional recoveries of tracer ET-1 and
albumin were determined. A plot of the fractional recoveries
per milliliter of blood as a function of time was then con-
structed to obtain the indicator-dilution curve for each tracer.
The albumin is used as a plasmatic vascular reference tracer.
Cardiac output can then be computed as follows:
∞




is the total amount of Evans blue dye–bound albu-
min injected, and the denominator represents the area under
the fractional recovery versus time curve for the same tracer.
The recirculating tracer is mathematically removed by means
of linear extrapolation of the exponential downslope on a
semilogarithmic plot. Mean tracer ET-1 extraction is calcu-
lated with the following equation:
∞ ∞
extraction = 1– ∫ET(t)dt/ ∫ alb(t)dt
0 0
where the right term represents the difference in the areas
of the fractional recovery versus time curves for tracer albu-
min and ET. Mean tracer ET-1 extraction will vary not only
with the activity of the removal process (ETB receptor densi-
ty and activity) but also with pulmonary blood flow. The
metabolic capacity of the lungs to clear ET-1 from the circu-
lation was thus evaluated by computation of the permeabili-
ty–surface area (PS) product for ET-1 removal. The PS prod-
uct, which is equivalent to a plasmatic clearance, is used to
describe the unidirectional uptake of permeating tracers by
using the indicator-dilution technique.11,12 We have previous-
ly validated the use of the PS product to evaluate pulmonary
removal of tracer ET-1 and demonstrated its stability over a
wide range of pulmonary blood flow, despite the expected
1138 Mathieu et al The Journal of Thoracic and
Cardiovascular Surgery
June 2001
variations in mean tracer ET extraction.4 The PS product for
ET-1 removal by the pulmonary circulation was computed as
follows:
PS = –Fp × ln(1 – Ext)
where Fp is the pulmonary plasma flow in milliliters per
second and Ext is mean tracer ET-1 extraction.
All values are reported as means ± SEM. Companion radi-
al and pulmonary artery ET-1 levels were compared by using
2-tailed paired t tests. Unpaired 2-tailed t tests were used to
compare data between the 2 groups. Hemodynamic data
(before and after the operation) were compared by using
paired t tests. Linear regression was used to detect correlation
between the cardiac index and mean tracer ET-1 extraction.
Results
The mean age in the CPB group (61.7 ± 2 years) was
not different from that of the beating heart group (64.4
± 3 years; P = .63). The average ejection fraction was
also similar at 0.61 ± 0.04 and 0.58 ± 0.05 for the CPB
and beating heart groups, respectively (P = .89). The
mean numbers of bypass grafts were 2.9 ± 0.3 and 2.5
± 0.2, respectively, for the CPB and beating heart
groups (P = .18). In the CPB group the average CPB
time was 65.0 ± 5.9 minutes, and the crossclamp time
was 44.6 ± 5.7 minutes. Before the operation, both
groups had similar heart rates, mean arterial blood
pressures, central venous pressures, and pulmonary
artery pressures (Table I). After the operation, heart rate
increased in the CPB group from 65 ± 3 beats/min to
75 ± 3 beats/min (P = .05), as did the cardiac index
from 2.4 ± 0.2 to 3.3 ± 0.1 L · min–1 · m–2 (P = .0003).
In the beating heart group hemodynamic parameters
were not affected by the procedure.
In the CPB group pulmonary artery ET-1 levels were
not modified, with means of 1.59 ± 0.37 pg/mL before
and 1.33 ± 0.15 pg/mL after the procedure (P = .45, Fig
1). Systemic levels measured in the radial artery, how-
ever, increased from 1.64 ± 0.22 pg/mL to 2.07 ± 0.16
pg/mL (P = .01). In the beating heart group mean lev-
els of ET-1 were not affected when compared with
respective preoperative value (Fig 2). Mean pulmonary
artery levels of ET-1 (1.25 ± 0.27 pg/mL and 1.45
pg/mL, respectively, before and after the procedure; P
= .38) and systemic levels measured in the radial artery
(1.70 ± 0.26 pg/mL and 1.73 ± 0.35 pg/mL, respective-
ly, before and after the operation; P = .92) were not dif-
ferent. Before the operation, there was no ET-1 gradi-
ent across the lungs in the CPB group, whereas there
was a significant 56% positive gradient after the oper-
ation (P = .0004). In the beating heart group there was
a significant 36% positive ET-1 gradient before the
operation (P = .01), which was reduced to 19% and no
longer significant after the operation (P = .01).
Mean pulmonary iodine 125–labeled ET-1 extraction
decreased after the operation in the CPB group from
40.9% ± 4.0% to 24.4% ± 4.7% (P = .0001) and was
not affected in the beating heart group (43.0% ± 6.0%
and 36.6% ± 6.1%, respectively, before and after the
operation; P = .2). The reduction in tracer ET-1 extrac-
tion in the CPB group correlated inversely with the
observed increase in cardiac index after the operation (r
= –0.43, P <.005). The pulmonary metabolic capacity
to clear ET-1 from the circulation, as computed from
the PS product, remained stable before and after the
operation in both the CPB group (25.2 ± 2.7 mL/s and
23.1 ± 4.4 mL/s, respectively; P = .49; Fig 3) and the
beating heart group (29.4 ± 5.4 mL/s and 27.7 ± 5.0
mL/s, respectively; P = .63; not shown).
Discussion
CPB is associated with a systemic inflammatory
response and the release of numerous vasoactive sub-
stances.13 Increased systemic levels of ET-1 during
CPB have previously been documented14 and are con-
firmed in the present study. There was a significant
positive arteriovenous ET-1 gradient in patients under-
going operations with CPB. It has been suggested that
the arteriovenous gradient is related to a decreased pul-
monary clearance of ET-1.14 However, a simple analy-
sis of the transpulmonary gradient, analogous to a
The Journal of Thoracic and
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Table I. Hemodynamic data in patients operated on with CPB and without CPB (beating heart group)
CPB Beating heart
Preoperative Postoperative Preoperative Postoperative
HR (beats/min) 65 ± 3 75 ± 3* 63 ± 4 69 ± 3
BP (mm Hg) 84 ± 2 80 ± 3 79 ± 2 76 ± 2
CVP (mm Hg) 10 ± 1 12 ± 1 10 ± 1 10 ± 2
MPA (mm Hg) 21 ± 2 21 ± 2 17 ± 2 20 ± 3
CI (L · min–1 · m–2) 2.4 ± 0.2 3.3 ± 0.1† 2.6 ± 0.3 2.5 ± 0.2
HR, Heart rate; BP, blood pressure; CVP, central venous pressure; MPA, mean pulmonary artery pressure; CI, cardiac index.
*P = .05, preoperative versus postoperative value in the CPB group.
†P = .0003, preoperative versus postoperative value in the CPB group.
black box analysis, does not provide all the information
about the pulmonary metabolism of ET-1. Use of the
indicator-dilution technique in combination with mea-
surements of arteriovenous ET-1 levels allows for dis-
crimination between removal and production within the
black box. Emphasizing this concept, we have shown
that the normal human pulmonary circulation demon-
strates minimal or no arteriovenous ET-1 gradient,
despite close to 50% tracer ET-1 extraction. The normal
lungs therefore produce and release ET-1 into the cir-
culation in an amount equal to the quantity extracted.6
Animal studies have established the lungs as one of the
major sites for ET-1 removal mediated through the
endothelial ETB receptor, as well as for ET-1 produc-
tion.15 Increased ET-1 transpulmonary gradients could
therefore be related to a decreased removal of ET-1, an
increase in production, or a combination of both. The
indicator-dilution technique combined with the mea-
surement of ET-1 has been used in this study to pre-
cisely quantify pulmonary ET-1 metabolism during
cardiac operations.
According to the model we used,11 mean pulmonary
tracer ET-1 extraction will correlate directly with the
activity of the removal process (endothelial ETB densi-
ty and activity) and the metabolically active pulmonary
vascular surface area but indirectly with pulmonary
plasma flow. We found that mean tracer ET-1 extraction
was significantly reduced after the surgical procedure
in the CPB group but that this correlated inversely with
the observed increase in cardiac index for the same
patients. Using isolated rat lungs, we have validated
this model and demonstrated that mean tracer ET-1
extraction varies inversely with increases in plasma
flow: the computed PS product, which accounts for this
variability, remains remarkably constant over a wide
range of blood flows, however.4 In fact, only in the
transition from very low to higher flow rates did we
find a tendency for an increase in the PS product, prob-
ably because of an increase in metabolically active sur-
face caused by lung capillary recruitment. In the pres-
ent study we found that the metabolic capacity of the
lungs to remove ET-1 from the circulation, as comput-
ed from the PS product, was similar in the CBP and
beating heart groups and did not vary after the surgical
procedure. This therefore suggests that the increased
transpulmonary ET-1 gradient observed in the CPB
group is not related to a decreased clearance but rather
to an increase in pulmonary ET-1 production and
release into circulation.
The hemodynamic effects of ET-1 are mediated by 2
receptor subtypes. The ETA receptors are located on the
vascular smooth muscle cells and mediate vasocon-
striction, whereas the ETB receptors are located on
endothelial cells, where they are responsible for
vasodilation through the production of nitric oxide and
prostacyclin.16 Endothelial ETB receptors are also
responsible for pulmonary clearance of ET-1,15 with
their blockade causing an increase in circulating ET-1
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Fig 1. Preoperative and postoperative plasma ET-1 levels
measured in the pulmonary and radial artery in the CPB
group.
Fig 2. Preoperative and postoperative plasma ET-1 levels
measured in the pulmonary and radial artery in the beating
heart group.
levels. The ETB receptors are also present on the vas-
cular smooth muscle, where they also mediate vaso-
constriction on stimulation. Rats with heart failure
caused by coronary artery ligation demonstrate reduced
pulmonary ET-1 clearance that correlates well with the
increase in circulating ET-1 levels.17 The reported
reduction in pulmonary ETB receptor density,18 as well
as ETB mRNA expression and protein level,19 in this
model support the hypothesis that a reduced pulmonary
ET-1 clearance is caused by endothelial dysfunction,
with reduced activity or density of the ETB receptor.
The present study suggests that CPB does not affect
endothelial ETB integrity and function because the pul-
monary removal of ET-1 was not affected by the pro-
cedure. The observed increase in systemic ET-1 levels
after CPB operations, but not after beating heart opera-
tions, must therefore be caused by an increased pul-
monary production and release of the peptide.
Before the operation, there was no pulmonary ET-1
gradient in the CPB group, although there was a posi-
tive 36% gradient in the beating heart group. This sug-
gests that the beating heart group had a net pulmonary
ET-1 release present at baseline, whereas the CPB
group, with no gradient, had a release that matched
removal. After the operation, the beating heart group
demonstrated no variation in systemic ET-1 levels and
demonstrated a positive, although no longer significant,
19% transpulmonary ET-1 gradient. Consequently,
even if baseline ET-1 equilibriums across the pul-
monary circulation were different between the 2
groups, possibly because of interindividual variability,
our data demonstrate that the balance was strongly
shifted to a net pulmonary release of ET-1 in the CPB
group (from no gradient to 56% positive gradient),
whereas in the beating heart group there was a tenden-
cy for a net reduction in ET-1 release by the lungs
(from 36% to 19% positive gradient).
The exact mechanisms behind the increased ET-1 con-
centration after CPB are unknown. However, surgical
stress20 and hypothermia21 are known to increase ET-1
levels. We failed to find any significant increase in both
mixed venous and arterial ET-1 levels in the beating
heart groups. This suggests that the surgical stress itself
was not the most important variable affecting ET-1 pro-
duction and that procedures associated with the CPB
itself are more important in the activation of the ET sys-
tem during cardiac operations. Although we have found
elevated concentrations of ET-1 after CPB, these circu-
lating levels are probably too low to exert any systemic
vasoactive effect. It is widely accepted that ET-1 is a
mostly paracrine mediator so that circulating ET-1 gen-
erally represents a local spillover indicative of increased
tissue ET-1 production, where concentrations may reach
pathophysiologic significance. This concept is supported
by a pathologic animal model in which post-CPB pul-
monary hypertension was reduced by acute ET receptor
blockade.22 In our patients the pulmonary artery pressure
did not significantly change before and after the proce-
dure in either group (CPB and beating heart group).
However, this was not surprising because those patients
had normal preoperative pulmonary artery pressure. In a
lamb model the pre-existing pulmonary circulation sta-
tus influences the pulmonary vascular resistance after
CPB.23 Consequently, in patients with pre-existing pul-
monary hypertension, it is possible that the local
increase in pulmonary production of ET-1 could be
greater and lead to significant deterioration of pul-
monary hemodynamics, although this remains specula-
tive at this point.
CABG with the beating heart technique avoids the
important inflammatory reaction observed with CPB.
CPB exposes blood to artificial membranes and trig-
gers an important inflammatory reaction.7 ET-1,
through its proinflammatory effects, could contribute
to this process. In vitro ET-1 stimulates monocytes and
macrophages to release tumor necrosis factor α, inter-
leukin 1β, and interleukin 8.24 The ET-1 proinflamma-
tory effects could affect the local and systemic inflam-
matory reaction. The exact roles of ET-1 as a
proinflammatory and vasoactive molecule during CPB
remain unknown.
This was a nonrandomized study in which the choice
of CABG with or without CPB was at the discretion of
the attending surgeon. Considering the small number of
patients in each group, a selection bias may have affect-
ed the results. The presence of a mild positive ET-1
gradient before the operation in the beating heart group
with no such gradient in the CPB group may be related
to these limitations.
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Fig 3. PS product in the CPB group: preoperative and post-
operative value (P = .49).
Within groups, paired comparisons, however, demon-
strated a net increase in arterial ET-1 only in the CPB
group, supporting our conclusion of an increased pul-
monary ET-1 production only in this group.
Conclusion
We have shown that CABG with CPB causes an
increase in ET-1 levels across the pulmonary circula-
tion. This is not related to a reduced pulmonary
removal of this peptide but rather to an increase in pul-
monary production and release into the circulation.
Operations with the beating heart technique did not
modify pulmonary ET-1 kinetics. Further studies are
needed to precisely identify the potential pathophysio-
logic role of ET-1 during CPB.
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